The End of Diabetes: The Eat to Live Plan to Prevent and Reverse Diabetes

<!–ACNTP

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(R) compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, presented a poster on the efficiency of NeutroPhase(R) solution (NVC-101) with the hydrophobic mesh Sorbact(R) in healing protracted non-healing wounds at the 2011 Symposium on Advanced Wound Care (SAWC) in Dallas on April 15-16. The poster, titled “NeutroPhase(R) with Sorbact(R) Dramatically Enhances the Velocity of Wound Healing,” was created by analysts at NovaBay and the San Francisco Center for Advanced Wound Care at the Seton Medical Center in Daly City, CA. The poster reported on multiple worked examples in the clinic in which a mixing of 0.01% NeutroPhase, (used as a fast-acting, broad spectrum anti-infective irrigant, capable of destroying biofilms associated with infections) with Sorbact (distributed by Trailblazer Technology, Inc. ) as a wound mesh dressing capable of reducing maceration of opposite skin and binding and inactivating pathogenic microbes, in association with Negative Pressure Wound Care (NPWT) administered to 26 patients with prolonged non-healing wounds.

These infected wounds were culture positive for a variety of pathogens which were successfully treated with NeutroPhase ; most significantly, methicillin-resistant staphylococcus aureus (MRSA), pseudomonas aeruginosa and vancomycin-resistant enterococci (VRE). The poster shows the clinical real-world example results from patients with non-healing wounds following amputation, a chronic venous girdle ulcer, a traumatic venous ulcer and a MRSA infection post radical excision of a squamous cell cancer with exposed cranial bone. The inability of these injuries to fix can be exacerbated by the presence of bacteria-rich biofilm. The analysts demonstrated that NeutroPhase was capable of destroying biofilm in the injuries without damaging the surrounding tissues and was an efficient topical anti-microbial that improved wound healing. Furthermore, Sorbact was found to help in reducing tissue maceration, a process in which the skin softens, turns white, and can simply get infected with bacteria or fungi. NovaBay has two FDA 510 (k) clearances for NeutroPhase(R) solution and has begun to go forward toward sizeable producing and eventual selling by its Hospice Business Unit.

NovaBay’s Infirmary targeted Business Unit directs all activities in relation to manufacturing, partnering and development of additional application of NeutroPhase. “Infected injuries don't heal!” asserted John Crew, MD, FACS, Vascular Surgeon and Medical Director of San Francisco Center for Advanced Wound Care at the Seton Clinic in Daly City, CA. And one of the poster’s co-authors. Doctor. Crew continued, “Biofilm linked with infected wounds can severely delay or repress wound healing making a contribution to the patients’ morbidity and mortality. These clinical case results are very inspiring. We are grateful to NovaBay and their research and development team for developing NeutroPhase for this growing patient population.

Furthermore, these case studies exhibit that NeutroPhase, applied in combination with Sorbact, was well-tolerated by the patients and has the potential to be a particularly effective wound care product. We have noted speeded up healing based mostly on historical experience and phenomenal versatility in terms of the sorts of wounds that may be successfully treated in this way. ” . To view the NeutroPhase poster, please follow this link : novabaypharma with Sorbact.pdf . About NeutroPhase(R) . NeutroPhase(R) is composed of pure and stable hypochlorous acid in saline.

NeutroPhase has broad spectrum anti-infective and anti-biofilm properties. The solution has been shown not to harm living cells and is rapidly useful against common wound pathogens. The traits and mechanisms of action of NeutroPhase make it very unlikely that resistant strains of bacteria could develop over a period. NeutroPhase has two 510 (k) clearances at 0.01% to 0.1% concentration. About NovaBay Pharmaceuticals, Incorporated.

These are novel, artificial anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and forestall a good range of local, non-systemic illnesses with a low possibility of developing bacterial resistance. NovaBay is focusing its technology on four distinct healing areas : dermatology, ophthalmology, urology and hospice diseases. In dermatology, the focus is on developing NVC-422 gel for impetigo and acne. NovaBay has the advantage of being partnered with Galderma, the premiere dermatology company worldwide.

In ophthalmology, the objective is to develop an eye drop for conjunctivitis with Alcon, the world's foremost ophthalmology company. In urology, NovaBay intends to scale back the incidence of urinary catheter blockage and encrustation (UCBE) and the capability for urine passage diseases with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing injuries, for example pressure, venous stasis and diabetic ulcers with its exclusive anti-infective solution, NeutroPhase, which has received 2 510 (k) clearances from the Food and Drug Administration. For extra information, visit novabaypharma prnewswire

ACNTPEND–>

The End of Diabetes: The Eat to Live Plan to Prevent and Reverse Diabetes